GlassScriptPhysician profile
Christopher Cooper
NPI 1154321057
$278,059.98
in general payments reported to CMS, 2019-2025
23 companies · $26K in 2025
The $26K reported for 2025 was more than what 96% of Infectious Disease providers received nationally (typical 2025 total: $187).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $49K · 2020: $2,849 · 2021: $37K · 2022: $45K · 2023: $70K · 2024: $48K · 2025: $26K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $79K · Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program: $28K · Travel and Lodging: $19K · Honoraria: $9,840 · Food and Beverage: $7,044 · Consulting Fee: $1,350 · Education: $81.87.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $78,627.50 |
| Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program | $28,190.00 |
| Travel and Lodging | $18,631.93 |
| Honoraria | $9,840.00 |
| Food and Beverage | $7,043.98 |
| Consulting Fee | $1,349.50 |
| Education | $81.87 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Paratek Pharmaceuticals, INC. | $95,492.90 | 2021-2025 | Nuzyra |
| Takeda Pharmaceuticals U.S.A., INC. | $54,208.35 | 2022-2025 | Livtencity |
| Merck Sharp & Dohme LLC | $49,360.09 | 2019-2025 | Zerbaxa, Dificid, Recarbrio |
| Shionogi INC | $38,254.93 | 2020-2025 | Fetroja |
| La Jolla Pharmaceutical Company | $20,111.13 | 2021-2025 | Xerava, Xacduro, Zevtera |
| Tetraphase Pharmaceuticals, INC. | $12,025.19 | 2019-2025 | |
| Melinta Therapeutics, LLC | $2,708.82 | 2019-2025 | Rezzayo, Kimyrsa, Vabomere |
| Astellas Pharma US INC | $2,081.77 | 2019-2025 | Cresemba |
| Insmed, INC. | $1,521.53 | 2019-2025 | Arikayce |
| Angiodynamics, INC. | $900.00 | 2019 | |
| Medtronic Vascular, INC. | $300.00 | 2019 | |
| Abbvie INC. | $260.54 | 2022-2025 | |
| Allergan, INC. | $180.08 | 2019-2020 | |
| Medtronic, INC. | $150.32 | 2021 | |
| Aimmune Therapeutics, INC. | $136.14 | 2024-2025 | Vowst |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Gilead Sciences, INC. | $126.96 | 2021-2023 | Veklury |
| Ferring Pharmaceuticals INC. | $83.46 | 2022-2025 | Rebyota |
| Cumberland Pharmaceuticals, INC. | $71.62 | 2021-2025 | Vibativ |
| Glaxosmithkline, LLC. | $28.83 | 2022 | |
| Smith+Nephew, INC. | $24.18 | 2024 | Collagenase Santyl |
| Mayne Pharma Commercial LLC | $15.66 | 2021 | |
| T2 Biosystems, INC. | $12.40 | 2019 | |
| Kerecis Limited | $5.08 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Christopher Cooper listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.